[go: up one dir, main page]

WO2016004250A3 - Caractérisation biologique d'un produit médicamenteux à l'acétate de glatiramère, à l'aide de cellules humaines et de mammifères - Google Patents

Caractérisation biologique d'un produit médicamenteux à l'acétate de glatiramère, à l'aide de cellules humaines et de mammifères Download PDF

Info

Publication number
WO2016004250A3
WO2016004250A3 PCT/US2015/038901 US2015038901W WO2016004250A3 WO 2016004250 A3 WO2016004250 A3 WO 2016004250A3 US 2015038901 W US2015038901 W US 2015038901W WO 2016004250 A3 WO2016004250 A3 WO 2016004250A3
Authority
WO
WIPO (PCT)
Prior art keywords
glatiramer acetate
drug product
acetate related
related drug
mammalian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/038901
Other languages
English (en)
Other versions
WO2016004250A2 (fr
Inventor
Michael Hayden
Fadi George TOWFIC
Sarah Elisabeth KOLITZ
Benjamin James ZESKIND
David Ladkani
Tal Hasson
Liat Hayardeny
Iris Grossman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Priority to CA2952849A priority Critical patent/CA2952849A1/fr
Priority to EP15814349.5A priority patent/EP3164710A4/fr
Publication of WO2016004250A2 publication Critical patent/WO2016004250A2/fr
Publication of WO2016004250A3 publication Critical patent/WO2016004250A3/fr
Priority to IL249686A priority patent/IL249686A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

abrégé trop long
PCT/US2015/038901 2014-07-01 2015-07-01 Caractérisation biologique d'un produit médicamenteux à l'acétate de glatiramère, à l'aide de cellules humaines et de mammifères Ceased WO2016004250A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2952849A CA2952849A1 (fr) 2014-07-01 2015-07-01 Caracterisation biologique d'un produit medicamenteux a l'acetate de glatiramere, a l'aide de cellules humaines et de mammiferes
EP15814349.5A EP3164710A4 (fr) 2014-07-01 2015-07-01 Caractérisation biologique d'un produit médicamenteux à l'acétate de glatiramère, à l'aide de cellules humaines et de mammifères
IL249686A IL249686A0 (en) 2014-07-01 2016-12-21 Biological characterization of a product related to glatiramer cetate using mammalian and human cells

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201462019857P 2014-07-01 2014-07-01
US62/019,857 2014-07-01
US201462020358P 2014-07-02 2014-07-02
US62/020,358 2014-07-02
US201462025953P 2014-07-17 2014-07-17
US62/025,953 2014-07-17
US201462047437P 2014-09-08 2014-09-08
US62/047,437 2014-09-08
US201462078369P 2014-11-11 2014-11-11
US62/078,369 2014-11-11
US201562134245P 2015-03-17 2015-03-17
US62/134,245 2015-03-17
US201562162308P 2015-05-15 2015-05-15
US62/162,308 2015-05-15

Publications (2)

Publication Number Publication Date
WO2016004250A2 WO2016004250A2 (fr) 2016-01-07
WO2016004250A3 true WO2016004250A3 (fr) 2016-03-17

Family

ID=55020098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/038901 Ceased WO2016004250A2 (fr) 2014-07-01 2015-07-01 Caractérisation biologique d'un produit médicamenteux à l'acétate de glatiramère, à l'aide de cellules humaines et de mammifères

Country Status (6)

Country Link
EP (1) EP3164710A4 (fr)
CA (1) CA2952849A1 (fr)
IL (1) IL249686A0 (fr)
TW (1) TW201610169A (fr)
UY (1) UY36197A (fr)
WO (1) WO2016004250A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45496A (fr) * 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
WO2018053109A1 (fr) * 2016-09-14 2018-03-22 Teva Pharmaceutical Industries Ltd. Caractérisation d'expression génique d'un produit médicamenteux associé à l'acétate de glatiramère dans des cellules humaines et de mammifères
RU2766360C2 (ru) 2017-10-16 2022-03-15 Ф. Хоффманн-Ля Рош Аг МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В
CN116637123B (zh) * 2023-06-07 2024-02-13 上海市东方医院（同济大学附属东方医院） 敲降或下调C15orf39基因表达的试剂在制备治疗胃癌的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053203A1 (en) * 2007-06-21 2011-03-03 D Alessandro Josephine S Copolymer assay

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053203A1 (en) * 2007-06-21 2011-03-03 D Alessandro Josephine S Copolymer assay

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAUC ET AL.: "Loci Associated with N-Glycosylation of Human Immunoglobulin G Show Pleiotropy with Autoimmune Diseases and Haematological Cancers.", PLOS GENET, vol. 9, no. 1, January 2013 (2013-01-01), pages 1 - 17, XP055139801 *

Also Published As

Publication number Publication date
CA2952849A1 (fr) 2016-01-07
WO2016004250A2 (fr) 2016-01-07
IL249686A0 (en) 2017-02-28
UY36197A (es) 2016-01-29
EP3164710A2 (fr) 2017-05-10
EP3164710A4 (fr) 2018-04-11
TW201610169A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
HK1216299A1 (zh) 表徵醋酸格拉替雷相关的药品
EP3728596A4 (fr) Construction d'acide nucléique permettant l'expression d'un gène in vitro et in vivo
EP4372078A3 (fr) Procédés pour la récolte de cultures de cellules de mammifères
WO2016015058A3 (fr) Procédés de détermination de types de tissus et/ou de cellules permettant d'obtenir de l'adn sans cellules, et procédés d'identification d'une maladie ou d'un trouble les employant
CA2975855C (fr) Compositions et methodes d'assemblage de gene synthetique
EP3359665C0 (fr) Précoce isolation post-transfection de cellules pour preparer des produits biologiques
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
EP4245859A3 (fr) Imagerie à débit et à multiplexage élevés au moyen de sondes nucléiques programmables
WO2016085632A3 (fr) Mesures microfluidiques de la réponse d'un organisme à un médicament
WO2015158808A3 (fr) Cellule hôte recombinée modifiée de sorte à surexprimer des protéines auxiliaires
EP3307164A4 (fr) Enzymes sensibles au lactate stabilisées, électrodes et capteurs, et procédés de fabrication et d'utilisation correspondants
MX366369B (es) Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo.
EP3186397A4 (fr) Utilisation de biomarqueurs de cellules circulant dans le sang pour la détection et le diagnostic de maladies, et leurs procédés d'isolement
EP3147656A3 (fr) Mesure de coefficient de dilatation thermique
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
WO2017013495A9 (fr) Compositions et procédés de mesure de la glycémie
EP4556571A3 (fr) Sondes oligonucleotidiques marquees par oxydo-reduction et leur utilisation
FR3017388B1 (fr) Procede de preparation d'elastomeres dieniques porteurs de fonctions phosphorees, produits issus de ce procede et composition les contenant.
WO2016144873A3 (fr) Procédés de marquage de cellules et d'imagerie médicale
WO2016004250A3 (fr) Caractérisation biologique d'un produit médicamenteux à l'acétate de glatiramère, à l'aide de cellules humaines et de mammifères
WO2016081885A3 (fr) Test de diagnostic génétique sur panel pour maladies oculaires héréditaires
EP3294132A4 (fr) Appareil de mesure de glycémie et procédé de mesure de glycémie correspondant
EP3619315A4 (fr) Produits protéiques unicellulaires et procédé intégré de production d'éthanol et de protéine unicellulaire
EP3264093A4 (fr) Procédé de diagnostic de maladie par analyse d'oligomère de protéines anormalement agrégées
HK1253320A1 (zh) 用於治療aml的藥物組合物和治療有此需要的對象中的aml的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15814349

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2952849

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2015814349

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015814349

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 249686

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15814349

Country of ref document: EP

Kind code of ref document: A2